Phaseline

Companies › Alpha Biopharma (Jiangsu)

Alpha Biopharma (Jiangsu): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Azd-3759
Epidermal growth factor receptor erbB1 inhibitor
EGFRPhase 1Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib TreatmentApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07361705Azd-3759Phase 1Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib TreatmentOncologyApr 2028

From the company's SEC filings

Complete response letters from FDA

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.